Equity Overview
Price & Market Data
Price: $28.76
Daily Change: -$0.11 / 0.38%
Range: $28.54 - $29.28
Market Cap: $1,895,200,640
Volume: 317,280
Performance Metrics
1 Week: 3.71%
1 Month: 8.53%
3 Months: 10.57%
6 Months: 5.70%
1 Year: 9.77%
YTD: 4.58%
Company Details
Employees: 704
Sector: Health technology
Industry: Biotechnology
Country: Belgium
Details
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.